Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
1.810
+0.010 (0.56%)
Oct 31, 2024, 4:00 PM EDT - Market closed
Aclaris Therapeutics Revenue
Aclaris Therapeutics had revenue of $2.77M in the quarter ending June 30, 2024, with 47.99% growth. This brings the company's revenue in the last twelve months to $32.02M, up 2.72% year-over-year. In the year 2023, Aclaris Therapeutics had annual revenue of $31.25M with 5.03% growth.
Revenue (ttm)
$32.02M
Revenue Growth
+2.72%
P/S Ratio
4.02
Revenue / Employee
$351,813
Employees
91
Market Cap
129.13M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 31.25M | 1.50M | 5.03% |
Dec 31, 2022 | 29.75M | 22.99M | 340.05% |
Dec 31, 2021 | 6.76M | 279.00K | 4.30% |
Dec 31, 2020 | 6.48M | 2.26M | 53.35% |
Dec 31, 2019 | 4.23M | -1.92M | -31.28% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Quipt Home Medical | 244.23M |
23andMe Holding Co. | 199.19M |
Rockwell Medical | 94.37M |
Journey Medical | 77.68M |
Scilex Holding Company | 50.83M |
Zomedica | 26.08M |
Seer, Inc. | 14.74M |
Werewolf Therapeutics | 9.28M |
ACRS News
- 6 weeks ago - Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis - GlobeNewsWire
- 7 weeks ago - Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference - GlobeNewsWire
- 3 months ago - Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million - GlobeNewsWire
- 4 months ago - Rheumatoid Arthritis Market and Epidemiology Forecast 2024-2034 Featuring Analysis of ATI-450 (Aclaris Therapeutics) and Olumiant/Baricitinib (Eli Lilly/Incyte) - GlobeNewsWire
- 5 months ago - Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference - GlobeNewsWire
- 6 months ago - American Clinical Research Services Announces Strategic Acquisition of Elixia - Business Wire
- 6 months ago - Aclaris Therapeutics, Inc. (ACRS) Q1 2024 Earnings Call Transcript - Seeking Alpha
- 6 months ago - Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire